Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sodium Diets on BP in Aliskiren-Treated Systolic Hypertension
NCT00441064Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aliskiren in isolated systolic hypertension (ISH) (2 arms), sponsored by Novartis. Primary endpoint: Mean 24 Hour Ambulatory Systolic Blood Pressure at 8 weeks. Started Jan 2007; status: completed.
02
Drugs
aliskiren
03
Conditions
isolated systolic hypertension (ISH)
Beyond the preview
Go deeper on NCT00441064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00441064.